Back to Journals » International Journal of Nephrology and Renovascular Disease » Volume 11

Anxiety and depression in patients with end-stage renal disease: impact and management challenges – a narrative review

Authors Goh ZS, Griva K

Received 10 October 2017

Accepted for publication 18 November 2017

Published 12 March 2018 Volume 2018:11 Pages 93—102

DOI https://doi.org/10.2147/IJNRD.S126615

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Professor Pravin Singhal


Zhong Sheng Goh, Konstadina Griva

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

Abstract: Psychiatric disorders commonly co-exist with the diagnosis of chronic kidney disease (CKD). Research on depression and CKD has increased to a great extent. Multiple studies have demonstrated that depression is more prevalent in CKD and that end-stage renal disease is a robust risk factor for adverse outcomes such as hospitalization and mortality, yet these are often underdiagnosed or untreated. This review provides a selective overview on the prevalence rates of depression and anxiety in patients with CKD and across renal replacement therapies, the factors most consistently associated with symptoms of distress and their clinical implications. Finally, treatment and management strategies from relevant literature are appraised and discussed.

Keywords: psychological, difficulties, symptoms, chronic kidney disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]